South San Francisco, California 94080

  • Dwarfism, Pituitary


This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.


Inclusion Criteria: - Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or greater) - Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater - Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk - Ability to keep follow-up appointments throughout the study - Willingness to remain on therapy until epiphyseal closure is achieved - Prior enrollment in NCGS Core Study 85-036 Exclusion Criteria: - Treatment with non-Genentech GH preparation - Closed epiphyses - Active neoplasia - Treatment with insulin for diabetes



Primary Contact:

Study Director
Barbara Lippe, M.D.

Backup Contact:


Location Contact:

South San Francisco, California 94080
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.